Gonadorelin: The Synthetic GnRH Decapeptide in the Research Literature

Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.

Gonadorelin is the synthetic form of native gonadotropin-releasing hormone (GnRH), a decapeptide first sequenced from pig and sheep hypothalami in 1971 and 1972. This article explains the sequence and its two unusual end groups, the receptor it binds and why that receptor is structurally odd among GPCRs, how the native decapeptide differs from analogs such as leuprolide, and the compound's regulatory history, which today consists of veterinary approvals and discontinued human products.

What gonadorelin is: the native GnRH decapeptide

Gonadorelin is pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂, the exact sequence of mammalian GnRH (also called GnRH-I or LHRH). Its formula is C₅₅H₇₅N₁₇O₁₃, molecular weight 1182.3, PubChem CID 638793, CAS 33515-09-2. The free base is rarely the article of commerce; approved veterinary products use the hydrochloride or the diacetate tetrahydrate, and research lots are usually acetate salts, so the certificate's salt line matters when converting label mass to moles, a calculation worked through in milligrams, micrograms and molarity.

Both ends of the chain are modified. The N-terminus is pyroglutamate (pGlu, also written 5-oxoproline), a glutamine that has cyclized onto itself and therefore carries no free amine. The C-terminus is a glycinamide. These caps are the reason native GnRH resists aminopeptidases and carboxypeptidases at the termini; the vulnerable bonds are internal, especially Tyr⁵-Gly⁶ and Gly⁶-Leu⁷, which endopeptidases cleave. That internal vulnerability is also the starting point for every analog described later in this article. For reading sequence notation, including the pGlu abbreviation and the -NH₂ suffix, see how to read a peptide sequence.

Discovery: the 1971 porcine and 1972 ovine sequences

The decapeptide was sequenced almost simultaneously by two competing groups, a race that ended in a shared Nobel Prize in 1977. Matsuo, Baba, Nair, Arimura and Schally reported the proposed porcine sequence in Biochemical and Biophysical Research Communications in June 1971, from material purified out of roughly 160,000 pig hypothalami, and the same group published in Science that year that a single peptide released both LH and FSH from pituitary tissue. Burgus, Guillemin and colleagues reported the ovine sequence in Proceedings of the National Academy of Sciences in January 1972, establishing it by chymotrypsin and pyrrolidone-carboxylyl-peptidase digestion, Edman-dansylation sequencing and mass spectrometry of the phenylthiohydantoin derivatives, and confirming it by total synthesis. The sheep and pig sequences were identical, and later work showed the same decapeptide across all mammals examined.

The PNAS paper is a useful early example of what a certificate of analysis does today: a synthetic decapeptide was prepared, sequenced by the same methods as the natural isolate, and shown to give the same result. Modern LC-MS identity confirmation of a gonadorelin lot is the direct descendant of that 1972 comparison; the LC-MS identity article explains what the mass spectrum proves and what it cannot.

The GnRH receptor: a GPCR with no tail

Gonadorelin binds the type I GnRH receptor (GnRHR, gene GNRHR), a class A G protein-coupled receptor cloned from human pituitary cDNA by Chi and colleagues in 1993 and encoding a 328-residue protein. The receptor couples predominantly through G_q/11, activating phospholipase C, inositol trisphosphate, calcium release and protein kinase C, a cascade reviewed in detail by Millar and colleagues in Endocrine Reviews in 2004 and by Naor in Frontiers in Neuroendocrinology in 2009. The GPCR primer covers the shared architecture.

What makes the mammalian type I GnRH receptor unusual is what it lacks: a cytoplasmic carboxyl-terminal tail. Almost every other rhodopsin-like GPCR carries a C-terminal tail that is phosphorylated after agonist binding, recruits beta-arrestin, and drives rapid desensitization and internalization. Pawson and colleagues showed in Endocrinology in 2008, using epitope-tagged receptors in cultured cells, that the mammalian receptor undergoes only slow, constitutive internalization that agonist does not accelerate, whereas the tailed catfish GnRH receptor and chimeras carrying a borrowed tail internalized briskly in response to agonist. The authors read this as an evolutionary adaptation that allows protracted signaling. Flanagan and Manilall's 2017 Frontiers in Endocrinology review maps the specific receptor residues that contact each part of the decapeptide, including the role of the pGlu and the Arg⁸ side chain in binding.

The first crystal structure arrived in 2020. Yan and colleagues reported in Nature Communications the human GnRH1R bound to the small-molecule antagonist elagolix at 2.8 angstrom resolution. The structure showed the receptor's own N-terminus folding into an enlarged orthosteric pocket alongside the ligand, and confirmed that the absence of a cytoplasmic C-terminal helix gives GnRH1R different microswitch features from other class A receptors. No peptide-bound structure of the native decapeptide was reported in that paper, so the binding mode of gonadorelin itself is still inferred from mutagenesis and docking.

How gonadorelin differs from leuprolide and other analogs

Gonadorelin is the reference compound from which the entire GnRH analog family was engineered, and the differences are specific, small, and chemically instructive. Karten and Rivier's 1986 Endocrine Reviews survey of more than a decade of structure-function work summarizes the two modifications that define the agonist class. First, replacing the achiral Gly⁶ with a D-amino acid blocks the main endopeptidase cleavage site and stabilizes the bioactive bent conformation. Second, replacing the C-terminal Gly¹⁰-NH₂ with an ethylamide on Pro⁹ removes a second cleavage site and raises receptor affinity. Antagonists went further, substituting D-amino acids at positions 1, 2, 3, 6 and 10.

Two consequences follow for a research lab. Chemically, the analogs are far more stable in plasma and tissue homogenates than gonadorelin, whose internal bonds are cleaved within minutes in such systems; a gonadorelin experiment is by nature short-lived unless protease inhibitors are present. Pharmacologically, native GnRH is released in pulses in vivo, and Millar's review notes that continuous versus pulsatile exposure produces opposite receptor-level outcomes in pituitary cell models. The analog literature therefore cannot be read as gonadorelin literature, and vice versa, even though all of them bind the same receptor. Gonadorelin is often studied with the upstream peptide covered in the kisspeptin-10 overview, since kisspeptin signaling is the principal input to GnRH neurons.

Regulatory history: discontinued human products, current veterinary approvals

Gonadorelin has an approval record in both human and veterinary medicine, and the two must be kept apart. On the human side, Drugs@FDA lists gonadorelin hydrochloride approved by the FDA as Factrel under NDA 018123 in September 1982, and gonadorelin acetate approved as the Lutrepulse kit under NDA 019687 in October 1989. Both human products are listed as discontinued; there is no human gonadorelin product currently marketed under an approved application in the United States. On the veterinary side, FDA's Center for Veterinary Medicine maintains approvals for cattle products, including gonadorelin hydrochloride approved as Factrel (Zoetis) and gonadorelin diacetate tetrahydrate approved as Cystorelin (Boehringer Ingelheim Animal Health), both of which carry labels on DailyMed. The veterinary literature, such as a 2015 Theriogenology comparison of different gonadorelin products in dairy cows by Poock and colleagues, concerns those approved products and their labeled uses in cattle.

A research-grade gonadorelin vial is none of these. It is not Factrel, not Cystorelin, not Lutrepulse, and not a compounded preparation. It is a laboratory reagent: synthesized and lyophilized in the USA, characterized by an independent US laboratory, and sold under a research-use-only attestation. For Gonadorelin 10 mg the lot-matched certificate reports identity by mass spectrometry against the expected mass of 1182.3, purity by HPLC, net peptide content, endotoxin, sterility and heavy metals, with the label mass referring to the lyophilized fill. The FDA status reference table records gonadorelin as "human products discontinued; veterinary approvals current."

Chemistry notes for the research vial

Three residues govern how gonadorelin behaves in the lab. Trp³ is light- and oxidation-sensitive and is the usual origin of a late-eluting impurity shoulder on HPLC. Tyr⁵ is the residue conventionally radio-iodinated or fluorescently tagged for binding assays, which is why many receptor papers refer to "[¹²⁵I]-GnRH" or tyrosine-labeled analogs. His² gives the peptide a pH-dependent charge near neutrality, so buffer choice shifts both solubility and HPLC retention. The pGlu N-terminus means the molecule has only one basic side chain (Arg⁸) plus the imidazole, so the counter-ion contribution to lyophilized mass is modest compared with a lysine-rich peptide; the net peptide content article explains how to read that line. Like most short amidated peptides, gonadorelin is stable as a dry lyophilizate when kept cold, dark and dry, and far less stable once in solution.

Frequently Asked Questions

Is gonadorelin the same as GnRH?

Yes. Gonadorelin is the nonproprietary name for the synthetic decapeptide with the exact mammalian GnRH sequence, pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂. LHRH and GnRH-I are older or alternative names for the same molecule.

What is the difference between gonadorelin and leuprolide?

Leuprolide replaces Gly⁶ with D-leucine and the C-terminal glycinamide with a proline ethylamide. Those two substitutions block the main cleavage sites and raise receptor affinity, which is why leuprolide is classed as a superagonist with a much longer action in biological systems, while gonadorelin is the short-lived native sequence.

Is gonadorelin approved by the FDA?

Human gonadorelin products were approved by the FDA as Factrel (1982) and Lutrepulse (1989) and are listed as discontinued. Current US approvals are veterinary: gonadorelin hydrochloride as Factrel and gonadorelin diacetate tetrahydrate as Cystorelin, for cattle. A research vial is not any of these products.

Why does the GnRH receptor lack a C-terminal tail?

The mammalian type I GnRH receptor is the only rhodopsin-like GPCR without a cytoplasmic C-terminal tail. A 2008 Endocrinology study showed that this makes the receptor internalize only slowly and independently of agonist, and the authors interpreted the missing tail as an adaptation that permits prolonged signaling.

Citations

1. Matsuo H, Baba Y, Nair RM, Arimura A, Schally AV. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun. 1971;43:1334-1339. PMID 4936338
2. Schally AV, Arimura A, Kastin AJ, et al. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science. 1971;173:1036-1038. PMID 4938639
3. Burgus R, Butcher M, Amoss M, et al. Primary structure of the ovine hypothalamic luteinizing hormone-releasing factor (LRF). Proc Natl Acad Sci USA. 1972;69:278-282. PMID 4550508
4. Chi L, Zhou W, Prikhozhan A, et al. Cloning and characterization of the human GnRH receptor. Mol Cell Endocrinol. 1993;91:R1-R6. PMID 8386108
5. Karten MJ, Rivier JE. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev. 1986;7:44-66. PMID 2420580
6. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing hormone receptors. Endocr Rev. 2004;25:235-275. PMID 15082521
7. Pawson AJ, Faccenda E, Maudsley S, Lu ZL, Naor Z, Millar RP. Mammalian type I gonadotropin-releasing hormone receptors undergo slow, constitutive, agonist-independent internalization. Endocrinology. 2008;149:1415-1422. PMID 18039780
8. Naor Z. Signaling by G-protein-coupled receptor (GPCR): studies on the GnRH receptor. Front Neuroendocrinol. 2009;30:10-29. PMID 18708085
9. Flanagan CA, Manilall A. Gonadotropin-Releasing Hormone (GnRH) Receptor Structure and GnRH Binding. Front Endocrinol. 2017;8:274. PMID 29123501
10. Yan W, Cheng L, Wang W, et al. Structure of the human gonadotropin-releasing hormone receptor GnRH1R reveals an unusual ligand binding mode. Nat Commun. 2020;11:5287. PMID 33082324
11. Poock SE, Lamberson WR, Lucy MC. Effect of different gonadorelin (GnRH) products used for the first or resynchronized timed artificial insemination on pregnancy rates in postpartum dairy cows. Theriogenology. 2015;84:504-508. PMID 25979657
12. US FDA. Drugs@FDA: NDA 018123 (Factrel, gonadorelin hydrochloride, 1982) and NDA 019687 (Lutrepulse, gonadorelin acetate, 1989), both discontinued. Drugs@FDA
13. DailyMed. Factrel (gonadorelin hydrochloride), Zoetis Inc.; Cystorelin (gonadorelin diacetate tetrahydrate), Boehringer Ingelheim Animal Health USA Inc. DailyMed
14. PubChem. Gonadorelin, CID 638793. PubChem

This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.

Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.